Medical Hypotheses
Volume 59, Issue 1 , Pages 98-100, July 2002

Anergy and chemokine receptors

  • H.R Hegde

      Affiliations

    • Corresponding Author InformationCorrespondence to: Hardally R. Hegde, MD, Peter Lougheed Centre, 3500-26th Avenue N.E., Calgary, Alberta Canada, T1Y 6J4

Department of Paediatrics, Peter Lougheed Centre, Calgary, Canada

Received 8 May 2001; accepted 31 October 2001.

Abstract 

The human immunodeficiency virus (HIV) induces a spectrum of immune abnormalities in the host by binding to CD4 molecules and chemokine receptors. Anergy, apoptosis, and immune activation are among the diverse immunological changes observed in the host. Chemokines, being the natural ligands for the chemokine receptors, block the entry of a retroviral strain, which exhibits tropism for the given receptor. This opens new therapeutic strategies and intervention possibilities for treating HIV-infected individuals.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 
  • 1 Abbreviations used: APC, Antigen presenting cell; CCR-5, Cysteine cysteine receptor-5; CD, Cluster of differentiation; MHC-II, Major histocompatibility complex protein-II; TCR, T-cell receptor; TGF-β, Transforming growth factor - beta.

PII: S0306-9877(02)00118-4

Medical Hypotheses
Volume 59, Issue 1 , Pages 98-100, July 2002

Article Tools

* Image Usage & Resolution